Accountants and valuators look at the same company through entirely different lenses. The GAAP balance sheet organizes assets and liabilities by liquidity and maturity. Damodaran's financial balance sheet reorganizes the same information to answer a different question: what assets generate value, and whose claims on those assets come first? Understanding this reorganization is the foundation for connecting accounting data to valuation models.
Accounting Balance Sheet vs. Financial Balance Sheet
The same business — reorganized for valuation rather than compliance reporting
GAAP Balance Sheet
Compliance view
ASSETS
LIABILITIES & EQUITY
Financial Balance Sheet
Valuation view
ASSETS (Reclassified)
Assets in Place
Existing operations — generate current NOPAT
Growth Assets
Future investments — value of ROIC > WACC
FINANCING (Reclassified)
Debt Claims
Fixed obligations; paid first; includes leases
Equity Claims
Residual claim; upside and downside
Key Differences — Why the Reclassification Matters
Working Capital Treatment
GAAP: Current assets minus current liabilities shown separately
Financial: Folded into 'assets in place' as invested capital
Growth Assets
GAAP: Not shown! R&D, brand, moat not on GAAP balance sheet
Financial: Explicitly shown as the PV of future ROIC > WACC investments
Debt vs. Equity
GAAP: Ordered by maturity (current vs. long-term)
Financial: Ordered by priority in liquidation (debt first, equity residual)
Figure 6.1 — The same $870M business viewed through two lenses. GAAP organizes for compliance; the financial balance sheet organizes for valuation — separating assets by their role (operating vs. growth) and claims by their priority (debt vs. equity).
The GAAP balance sheet is organized around two questions: how liquid are the assets? (current vs. non-current) and how soon are the obligations due? (current vs. long-term liabilities). This organization serves creditors and short-term liquidity analysts well. But it tells a valuator almost nothing about where value comes from or who has a claim to it. Damodaran reorganizes the balance sheet to answer the valuator's questions directly.
| GAAP Balance Sheet | Financial Balance Sheet | |
|---|---|---|
| Current assets (cash, inventory, receivables) | → Becomes → | Assets-in-place: existing operations already generating cash flows |
| PP&E, goodwill, intangibles | → Part of → | Assets-in-place (existing productive capacity) |
| [Not on GAAP balance sheet] | → Added as → | Growth assets: value of future investment opportunities not yet undertaken |
| Current liabilities, long-term debt, lease obligations | → Becomes → | Debt claims: fixed obligations that must be paid before equity holders receive anything |
| Common equity, retained earnings, APIC | → Becomes → | Equity claims: residual interest after all debt is satisfied |
| Minority interest | → Becomes → | Part of equity claims (belongs to outside shareholders of subsidiaries) |
The GAAP balance sheet does not show growth assets — investments in future projects not yet undertaken. Yet for a high-growth company like Amazon, Nvidia, or a biotech in Phase III trials, growth assets are often the majority of the company's total value. Damodaran's financial balance sheet makes this explicit: total assets = assets-in-place + growth assets. The valuator's job is to estimate both — assets-in-place through analysis of current operations, and growth assets through scenario analysis of future investment opportunities.
Every company's intrinsic value comes from two distinct sources. Assets-in-place are the existing operations, infrastructure, customer relationships, and productive capacity that generate current period cash flows. Growth assets are the options on future investments — the ability to expand into new markets, launch new products, or scale existing operations. The relative importance of each varies enormously by company type and stage:
| Company Type | % Value from Assets-in-Place | % Value from Growth Assets | Implication |
|---|---|---|---|
| Utility (regulated) | 85–95% | 5–15% | Almost all value from existing regulated cash flows; predictable; low uncertainty; low discount rate |
| Mature consumer staples | 70–80% | 20–30% | Mostly from existing brands/distribution; growth from market share and emerging markets |
| Industrial conglomerate | 60–70% | 30–40% | Mix of steady operations and reinvestment in capex and bolt-on acquisitions |
| Technology platform (mature) | 40–60% | 40–60% | Substantial growth option value from adjacent markets; significant but not dominant |
| High-growth software / SaaS | 10–30% | 70–90% | Most value from future growth — current revenues are a small fraction of eventual potential |
| Pre-revenue biotech | 0–5% | 95–100% | Almost entirely option value on drug pipeline; massive uncertainty around growth assets |
The more of a company's value that comes from growth assets (future options not yet exercised), the harder and more uncertain the valuation. Assets-in-place can be valued relatively precisely from current financial statements. Growth assets require forecasting future investments, future returns on those investments, and the future competitive environment in which they will operate. For pre-revenue biotech, you are valuing the probability-weighted outcome of drug trials that haven't concluded yet. This is why Damodaran says the five truths about valuation (especially uncertainty and bias) become more acute the higher the growth asset proportion.
The right side of the financial balance sheet represents two fundamentally different types of claims on the same pool of assets. Debt holders have a contractual, priority claim — they receive fixed interest and principal payments before equity holders receive anything. Equity holders have a residual claim — they receive whatever is left after all obligations to debt holders are met. This priority structure has profound implications for valuation:
Enterprise Value to Equity Value Bridge
Equity Value = Enterprise Value − Net Debt = EV − (Total Debt + Capital Leases − Cash)
Also subtract minority interest, unfunded pension obligations, and other debt-like claims
The financial balance sheet framework makes explicit which items flow into each type of valuation model. Understanding these connections prevents the most common structural errors in DCF models:
| Financial Statement Item | Role in Valuation | Common Error |
|---|---|---|
| EBIT or NOPAT (from income statement) | Measures operating profitability before financing costs — the numerator in ROIC and the starting point for FCFF | Including interest income/expense in FCFF (already in the discount rate) |
| Invested capital (from balance sheet) | PP&E + working capital + intangibles = the total capital employed in operations; denominator of ROIC | Forgetting to subtract excess cash (which is not deployed in operations) |
| Cash and equivalents | Subtracted from debt to get net debt; subtracted from enterprise value to get equity value | Counting cash twice — as both an asset in the DCF and as reducing net debt |
| Depreciation and amortization | Non-cash charge added back in the indirect cash flow method; must be distinguished from real capex needs | Using D&A as a proxy for maintenance capex — dangerous for capital-intensive businesses |
| Capital expenditures | Cash outflow that reduces free cash flow; split into maintenance (to sustain existing assets) and growth (to create new assets) | Using total capex in the terminal value — terminal value should reflect only maintenance capex if growth is already captured |
| Working capital changes | Increase in working capital = use of cash (reduces FCF); decrease = source of cash | Missing the working capital build required to support revenue growth forecasts |
The cleanest route from financial statements to FCFF: FCFF = EBIT × (1 − tax rate) + D&A − Capex − ΔWorking Capital. This is NOPAT (operating profit after tax, ignoring financing) plus non-cash charges (D&A) minus reinvestment (capex and working capital). The result is the cash flow available to all capital providers — debt and equity — before any financing payments. Discount this at WACC to get enterprise value. Subtract net debt to get equity value. Divide by diluted share count to get intrinsic value per share.
Key Takeaways
A biotech company has $50M in assets-in-place (a research facility, cash, and equipment) and a drug in Phase III trials with a 60% probability of FDA approval. If approved, the drug is estimated to generate $2B in NPV. The company has $100M in debt and 10M diluted shares. What is the intrinsic value per share?